scientia

Current Trends in Management of Blood Glucose in Type 2 Diabetes Mellitus


Program Description / Statement of Need:

Type 2 diabetes mellitus, the sixth leading cause of death in the U.S., is directly responsible for more then 73,000 deaths annually and is a contributing factor in more than 220,000 deaths.  More than 20 million Americans have diabetes of which 6 million are undiagnosed.  It is the leading cause of kidney failure and blindness in adults.  Evidence-based guidelines for the management of Type 2 diabetes focus on three areas: lifestyle changes (that include diet, exercise and weight loss); management of cardiovascular disease risk factors (including hypertension, dyslipidemia  and microalbuminuria with the use of aspirin, statins and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers); and management of blood glucose levels with pharmacotherapy. 

 

The Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes identified metformin, insulin and sulfonylureas as first-tier agents and GLP-1 agonist (exenatide) and thiazolidinediones (TZDs or glitazones) as second-tier agents for management of blood glucose levels.  The amylin agonists, alpha-glucosidase inhibitors, glinides and DPP-4 inhibitors were not included in their two tiers of preferred agents, though they may be appropriate choices in selected patients.  Partially in response to this Consensus Statement, the American Association of Clinical Endocrinologists and the American College of Endocrinology convened a consensus panel and issued their statement on glycemic control in Type 2 diabetes.  In developing their treatment algorithm, they set as priorities minimizing the risk and severity of hypoglycemia and minimizing the risk and magnitude of weight gain.   Consequently, the AACE/ACE Diabetes algorithm for glycemic control features a more prominent role for the DPP-4 inhibitors and amylin agonists due to impact on weight (DPP-4 – weight neutral; amylin agonists – weight loss) and their lack of hypoglycemia.


 

Target Audience:
This activity has been designed to meet the educational needs of Physicians, Nurses, Physician Assistants, Nurse Practitioners, and other health care professionals who are interested in managing patients with Type 2 Diabetes Mellitus (T2DM).

Program Objectives:

The learning objectives for this program are to enable participants, at the conclusion of the program, to able to:

    • Describe the similarities and differences between the two current treatment algorithms for the management of blood glucose levels in Type 2 diabetes
    • Identify the medications that have a positive or negative impact on weight in each of the treatment algorithms
    • Identify the medications that may cause hypoglycemia in each of the treatment algorithms
    • Recognize the appropriate therapeutic choices in individual patients based on their demographic and clinical characteristics

    Accreditation: (Accreditation Pending)

     

    Physicians: (Accreditation Pending) This program has been reviewed and is acceptable for up to 1 Prescribed credit hours by The American Academy of Family Physicians (AAFP). AAFP Prescribed credit is accepted by The AMA as equivalent to AMA PRA Category I for AMA The Physicians' Recognition Award. When applying for the AMA PRA, Prescribed hours earned must be reported as Prescribed hours, not as Category I. (This statement applies to all Physicians, not just Family Physicians). Educational Review Systems is also approved for physician continuing education by the state of Florida.

     

    Pharmacists: (Accreditation Pending) Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1 hour (0.1CEUs). ACPE # Pending Educational Review Systems is also approved for pharmacy continuing education by the state of Florida.

     

    Release Date: November 10, 2010
    Expiration Date: November 9, 2011

     

    Privacy Policy

    Faculty: Susan Cornell, PharmD.

     

    Faculty Disclosure and Resolution of COI

     

    As an provider of continuing medical education, it is the policy of the ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is our policy to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by the accredited provider(s) and/or ScientiaCME.

     

    Faculty Disclosure: Susan Cornell, PharmD discloses that she is on the Professional Speaker's Bureau for Johnson & Johnson Diabetes Institute, Novo-Nordisk, Merck, Takeda, and Abbott Diabetes Care.

     

    She has has performed consulting and/or honoraria received from: Editorial Advisory Board: The Kestrel Diabetes Product Sourcebook, Kestrel Health Information; Advanced Studies in Medicine: Endocrinology Advisory Board, Johns Hopkins;Speaker's Bureau for Johnson & Johnson Diabetes Institute, Novo-Nordisk, Merck, Takeda, and Abbott Diabetes Care.

     

    Disclosures of Educational Planners: Steven Sachse is an officer and part owner of ScientiaCME, LLC. ScientiaCME has received grants from Bayer, Edwards Lifesciences, Eisai, Daiichi-Sankyo, Lilly, Merck, Pfizer, Sanofi Aventis, Wolf-Torey Medical, and currently has grants pending from from Abbott, AMGEN, BMS, Eisai, and Savient Pharmaceuticals.

     

    Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC. ScientiaCME has received grants from Bayer, Edwards Lifesciences, Eisai, Daiichi-Sankyo, Lilly, Merck, Pfizer, Sanofi Aventis, Wolf-Torey Medical, and currently has grants pending from from Abbott, AMGEN, BMS, Eisai, and Savient Pharmaceuticals.

     

    Commercial Support Disclosure: This program is supported by educational grants from Daiichi-Sankyo and Merck.

    Viewing Requirements:

    PC Windows 2000 or above
    Internet Explorer 5.5
    *Adobe Acrobat Reader
    *Required to view Printable PDF Version
    MAC
    Mac OS 10.2.8
    Safari
    *Adobe Acrobat Reader
    Internet Explorer is not supported on the Macintosh

    On-line symposium:


      Instructions:
    • Read the learning objectives and faculty disclosures above
    • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
    • View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
    • Take the post-test
    • Complete the program evaluation and CME registration. A CE certificate will be emailed to you within 30 days.

    Perform Pre-Test (optional)


    Download the Presentation (optional)


     

    View the on-line program

     

    Perform Post-Test


    Complete the Symposium Evaluation and Request CE Certificate

    Supported through an educational grant from:

    Daiichi-Sankyo and Merck.    

     


    Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.